Does Blue Cross Blue Shield of Arizona Cover Ozempic?

How BCBSAZ Classifies Ozempic on Its Formulary

Blue Cross Blue Shield of Arizona places Ozempic (semaglutide injection) on its drug formulary as a covered benefit for adults with type 2 diabetes mellitus. The specific tier varies by plan design, but most commercial PPO and HMO products list Ozempic on Tier 3 or Tier 4.

Tier placement matters because it directly determines your copay or coinsurance percentage. A Tier 3 placement on a standard BCBSAZ commercial plan typically carries a copay between $50 and $100 per 28-day fill, while Tier 4 placement may require 25% to 40% coinsurance on the drug's list price. Ozempic's wholesale acquisition cost runs approximately $935.77 per monthly pen as of early 2026 [1]. That means coinsurance on a Tier 4 plan could exceed $200 before any manufacturer discount applies.

The American Diabetes Association's Standards of Care recommend GLP-1 receptor agonists as second-line therapy for patients with type 2 diabetes and established atherosclerotic cardiovascular disease or high cardiovascular risk, regardless of baseline HbA1c [2]. This guideline positioning strengthens the clinical case for Ozempic coverage when submitting prior authorization requests. BCBSAZ formulary documents reference ADA guidelines directly when outlining medical necessity criteria for GLP-1 agents.

For Medicare Advantage plans administered by BCBSAZ, Ozempic falls under Part D prescription drug coverage. The 2025 Inflation Reduction Act provisions cap annual out-of-pocket Part D spending at $2,000, which may reduce the total yearly burden for Medicare enrollees using Ozempic [3]. Plans vary, so members should verify their specific Summary of Benefits.

Prior Authorization Requirements You Should Expect

Nearly every BCBSAZ plan requires prior authorization before Ozempic can be dispensed at a pharmacy. This is standard across most commercial insurers for GLP-1 receptor agonists and not unique to Arizona.

The prior authorization process requires your prescribing clinician to submit clinical documentation to BCBSAZ demonstrating three things: a confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x), a current HbA1c value (most plans require HbA1c of 7.0% or above at initiation), and evidence that first-line therapy with metformin has been tried for at least 90 days or is contraindicated. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of type 2 diabetes states that "GLP-1 receptor agonists should be considered as first injectable therapy in patients who do not achieve glycemic targets with oral agents" [4]. This language can support prior authorization submissions when metformin alone has proven insufficient.

BCBSAZ typically processes prior authorization requests within 72 hours for standard requests and 24 hours for urgent requests. If approved, authorizations are usually valid for 12 months before requiring renewal. Denials can be appealed. The first-level appeal should include updated lab values, a letter of medical necessity from the prescriber, and any relevant specialist notes.

One practical tip: ask your provider's office to include the specific HbA1c reduction target and any cardiovascular risk factors in the prior authorization submission. BCBSAZ reviewers weigh cardiovascular benefit data heavily because the SUSTAIN-6 trial (N=3,297) demonstrated that semaglutide reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26% compared to placebo in patients with type 2 diabetes and high cardiovascular risk (HR 0.74 to 95% CI 0.58-0.95, P=0.016) [5].

Step Therapy: What BCBSAZ Requires Before Approving Ozempic

Step therapy is BCBSAZ's cost management protocol that requires patients to try less expensive medications before the insurer will cover a higher-cost drug. For Ozempic, the standard step therapy requirement on most BCBSAZ commercial plans is a documented trial of metformin at maximally tolerated doses for a minimum of 90 days.

Some plans impose a second step as well. This may require trying a sulfonylurea (such as glimepiride or glipizide) or an SGLT2 inhibitor (such as empagliflozin or dapagliflozin) before Ozempic is approved. The exact step therapy protocol depends on your specific BCBSAZ plan. Employer-sponsored plans often have customized formularies that may add or remove step requirements.

Patients who cannot tolerate metformin due to gastrointestinal side effects or who have an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² can request a step therapy exception. The FDA label for metformin notes it is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) [6]. Documenting this contraindication in the prior authorization submission typically allows providers to bypass the metformin step entirely.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has noted that "step therapy requirements that delay access to GLP-1 receptor agonists can lead to prolonged periods of suboptimal glycemic control, which increases the risk of diabetes-related complications" [7]. If your provider believes step therapy is clinically inappropriate for your situation, they can file a step therapy exception request directly with BCBSAZ.

What Ozempic Costs with BCBSAZ Insurance

Your actual out-of-pocket cost for Ozempic under a BCBSAZ plan depends on your tier placement, whether you have met your deductible, and whether you qualify for manufacturer assistance.

For a BCBSAZ commercial PPO plan with Tier 3 placement and a standard copay structure, expect to pay between $50 and $100 per 28-day pen after prior authorization approval. High-deductible health plans (HDHPs) paired with a health savings account require you to pay the full negotiated rate until your deductible is met. The negotiated rate between BCBSAZ and pharmacies for Ozempic varies but typically falls between $800 and $950 per pen.

Novo Nordisk's Ozempic Savings Card can reduce the cost to as low as $25 per month for commercially insured patients who meet eligibility criteria. The card is not valid for patients covered by Medicare, Medicaid, Tricare, or other government-funded programs [8]. Eligible patients can apply through the manufacturer's savings program and present the card at their pharmacy alongside their BCBSAZ insurance card.

For BCBSAZ Medicare Advantage Part D enrollees, the cost structure follows the standard Part D benefit design. After the $590 deductible (2025 amount), most plans cover 75% of the drug cost during the initial coverage phase. Once total out-of-pocket spending reaches $2 to 000 in a calendar year, catastrophic coverage begins and the patient pays $0 for covered drugs for the remainder of the year [3]. Given Ozempic's list price, a Medicare Advantage enrollee could reach the $2,000 cap within the first three to four months of the year.

A 2023 analysis published in Diabetes Care found that among commercially insured patients prescribed semaglutide, the median out-of-pocket cost was $47 per fill for those with prior authorization approval, compared to $935 for those paying cash without insurance [9]. That gap underscores the financial importance of completing the prior authorization process.

Ozempic for Weight Loss: What BCBSAZ Does and Does Not Cover

This distinction is critical. Ozempic is FDA-approved only for type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes and known heart disease [10]. It is not FDA-approved for weight management. Wegovy (semaglutide 2.4 mg) is the FDA-approved formulation for chronic weight management.

BCBSAZ does not cover Ozempic when prescribed off-label solely for weight loss. If a provider submits a prior authorization for Ozempic with an obesity diagnosis code (E66.01) and no type 2 diabetes diagnosis, the claim will be denied.

Some BCBSAZ employer-sponsored plans include an obesity benefit rider that covers FDA-approved anti-obesity medications. If your plan includes this rider, Wegovy may be covered with its own separate prior authorization process. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes (HR 0.80 to 95% CI 0.72-0.90, P<0.001) [11]. This cardiovascular benefit data has led some insurers, including certain BCBSAZ employer plans, to expand coverage of Wegovy for qualifying patients.

To determine whether your specific BCBSAZ plan includes an obesity medication benefit, call the member services number on the back of your insurance card or log into the BCBSAZ member portal to review your Summary of Benefits and Coverage document.

Alternatives If BCBSAZ Denies Ozempic Coverage

If your prior authorization is denied, you have several options beyond the standard appeal process.

Trulicity (dulaglutide) is another GLP-1 receptor agonist that is sometimes placed on a lower formulary tier than Ozempic on BCBSAZ plans. The REWIND trial (N=9,901) showed dulaglutide reduced major cardiovascular events by 12% versus placebo (HR 0.88 to 95% CI 0.79-0.99, P=0.026) [12]. While the cardiovascular benefit was numerically smaller than semaglutide's in SUSTAIN-6, dulaglutide remains a clinically effective GLP-1 option that may cost less under your specific plan.

Rybelsus (oral semaglutide 7 mg and 14 mg) offers the same active molecule as Ozempic in a daily oral tablet form. Some BCBSAZ plans place Rybelsus on a different tier than injectable Ozempic, and it may carry a lower copay. The PIONEER-1 trial (N=703) demonstrated that oral semaglutide 14 mg reduced HbA1c by 1.5 percentage points versus 0.0 for placebo at 26 weeks [13].

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist that some BCBSAZ plans now include on formulary. The SURPASS-2 trial (N=1,879) showed tirzepatide 15 mg reduced HbA1c by 2.58 percentage points versus 1.86 for semaglutide 1 mg [14]. Tirzepatide's formulary status on BCBSAZ plans varies widely, so check your specific plan documents.

The ADA's 2024 Standards of Care note that "when cost is a major barrier, clinicians should discuss lower-cost alternatives within the same drug class or consider patient assistance programs" [2]. Providers can also prescribe compounded semaglutide from 503A or 503B pharmacies, though BCBSAZ does not cover compounded medications, and the FDA has raised safety concerns about compounded semaglutide products [15].

How to Maximize Your Chances of Getting Ozempic Covered

Getting Ozempic approved through BCBSAZ comes down to thorough documentation and proper clinical framing. Start by confirming your plan's specific formulary and prior authorization criteria through the BCBSAZ provider portal or by calling pharmacy benefits at (602) 864-4400 or the number on your member ID card.

Your provider should document the following in the prior authorization submission: confirmed type 2 diabetes diagnosis with date of onset, most recent HbA1c (ideally within 90 days of the request), list of all diabetes medications tried with dates and outcomes, reason for metformin failure or contraindication (if applicable), and any cardiovascular risk factors including history of myocardial infarction, stroke, or peripheral arterial disease.

Cardiovascular history is particularly powerful in prior authorization requests. The FDA expanded Ozempic's labeling in 2024 to include a cardiovascular risk reduction indication based on data from SUSTAIN-6 and the broader SOUL trial program [5]. Highlighting this indication in the submission letter gives the BCBSAZ reviewer a clear, label-supported justification for approval.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has stated that "insurance barriers to GLP-1 receptor agonists remain one of the most significant obstacles to evidence-based diabetes care in the United States" [16]. If you receive a denial, do not stop at the first appeal. BCBSAZ allows two levels of internal appeal, followed by an external review through the Arizona Department of Insurance and Financial Institutions. Each level of review provides an additional opportunity to present clinical evidence supporting medical necessity.

Keep detailed records of all communications with BCBSAZ, including reference numbers, dates, and the names of representatives you speak with. Arizona law (A.R.S. § 20-3102) requires insurers to process prior authorization requests within specific timeframes and provide written explanations for denials.

Arizona-Specific Insurance Regulations That Affect GLP-1 Coverage

Arizona has enacted several insurance regulations that may help patients seeking GLP-1 coverage. The Arizona Department of Insurance and Financial Institutions oversees compliance with state-mandated benefits and consumer protection requirements for all plans regulated at the state level.

Arizona's external review statute (A.R.S. § 20-2537) allows patients to request an independent external review of any adverse benefit determination after exhausting internal appeals. The external reviewer is a physician who is not employed by BCBSAZ and who reviews the clinical evidence independently. External reviews overturn insurer denials in approximately 40% to 50% of cases nationally, according to data from the Kaiser Family Foundation [17].

Self-funded employer plans (ERISA plans) are exempt from Arizona state insurance mandates because they are regulated under federal law. If your BCBSAZ coverage is through a self-funded employer plan, the appeals process and coverage criteria may differ from those of fully insured plans. Check your plan document (often called the Summary Plan Description) to determine whether your plan is self-funded or fully insured.

For Arizona Medicaid (AHCCCS) enrollees, Ozempic coverage falls under the AHCCCS pharmacy benefit. AHCCCS maintains its own preferred drug list, which is separate from BCBSAZ commercial formularies. GLP-1 receptor agonists are covered under AHCCCS for type 2 diabetes with prior authorization, but the preferred agent may differ from what BCBSAZ commercial plans cover [18].